A combination of two potential drugs gives hope of a ‘super blockage’ of an over-active immune system, Leiden researchers report in Nature. The breakthrough came from the crystallisation of a membrane protein.
Over-alert immune system
Our immune system is intended to protect the body against infiltrators. But sometimes it behaves too alertly, attacking the body itself. This results in chronic inflammation, such as multiple sclerosis, rheumatism or osteoarthritis.
Inhibiting inflammatory reactions
Laura Heitman, Ad IJzerman, Henk de Vries and Natalia Ortiz Zacarias from the Leiden Academic Centre for Drug Research (LACDR) are publishing their research this week in the journal Nature, research that may lead to a more effective way of inhibiting these responses. Their research focuses on the CCR2 receptor. The Leiden researchers work closely with an American team headed by Tracy Handel and Irina Kufureva.
Keyhole at nanoscale
A receptor is a kind of keyhole at nanoscale on the outside of a cell – in the cell membrane – into which a specific key molecule fits. The immune system comprises all kinds of immune cells, each with different types of receptors. The key molecules are called chemokines, and are produced by cells in diseased tissue. Immune cells are attracted automatically towards higher concentrations of chemokine, which generally means towards parts of the body where they are needed.
But patients with rheumatism or osteoarthritis produce too much CCL2, the chemokine for the CCR2 receptor. Although there are ways of blocking the CCR2 receptor, which in turn inhibits the inflammation, the inhibitors currently available prove to be largely ineffective in humans.
In order to discover how this process works at atomic level, Heitman and her colleagues examined the CCR2 protein using X-rays. This cannot be done using whole cells or a fragment of the cell membrane, where other proteins are also present. The researchers needed to have the CCR2 protein in very pure crystal form. This had never previously been done successfully. Laura Heitman: ‘If you take this kind of protein from the cell membrane, it’s very difficult to crystallise it.’
Thanks to this advance, researchers now have a detailed understanding of the three-dimensional form of the CCR2 protein, which is a good starting point for further research on the interaction beteween CCR2 and the related CCL2 chemokine.The research had immediate results: crystallisation was only possible if two inhibitors (BMS-681 and CCR2-RA-[R]) are both added to the CCR2 protein.
Possible duo medicine
Heitman: ‘This suggests a new strategy: duo therapy. By administering these two substances at the same time, you get a kind of “super blockage” of the CCR2 receptor, which is more effective than administering the two substances separately.’ Heitman refers to these substances deliberately as ‘potential medicines’: this is just the start of a process that could lead to a new duo medicine.
Heitman’s group will first continue their work with other receptors, CCR1 and CCR3 up to and including CCR9 before considering other super inhibitors. The ultimate aim is to manipulate the immune system so effectively that it only has beneficial effects, and the detrimental effects are excluded.
Learn more: Two-pronged attack on infectious diseases
Receive an email update when we add a new IMMUNE SYSTEM article.
The Latest on: Overactive immune system
via Google News
The Latest on: Overactive immune system
- Cancer: Inactive receptor renders immunotherapies ineffectiveon October 14, 2019 at 8:52 am
An overactive immune system can be nearly as dangerous as an inactive one, triggering inflammation that attacks the body’s own tissues. To counter this, the immune system has what are known as ...
- Leukemia immunotherapy treatment could fight other cancers, Tel Aviv team findson October 14, 2019 at 8:38 am
The process leads to side effects, which can include severe inflammation produced by an overactive immune system, but the drawbacks are less severe than those associated with chemotherapy. The T cell ...
- Inactive receptor renders immunotherapies ineffectiveon October 14, 2019 at 6:04 am
Based on analysis of human tissue samples, a team from the Technical University of Munich (TUM) has now discovered one reason why this is so: an inactive receptor in cancer cells prevents the drugs ...
- Healthcare Companies Seek Innovative Ways to Combat New Diseaseson October 1, 2019 at 6:04 am
Hussein Tawbi, M.D., Ph.D., of the University of Texas MD Anderson Cancer Center, mentioned that having an overactive immune system is the main reason why patients with both cancer and autoimmune ...
- overactive immune systemon August 21, 2019 at 5:00 pm
[LONDON] Scientists exploring what may trigger a complex disorder known as chronic fatigue syndrome (CFS) have found clues in the way some people's immune systems respond more actively to a ...
- New Method for Tackling Stroke Restrains an Overactive Immune Systemon July 2, 2019 at 3:16 pm
This deprivation results in injury and death to the local brain cells. But for days after the breach in blood flow, the immune system also does its own fair share of damage to the already injured ...
- Overactive Innate Immunity Tied to Higher Stroke Riskon June 18, 2019 at 2:00 pm
"As the markers increase over time, it increased risk...and this represents an overactive immune system." In contrast, higher lymphocyte counts conferred a decreased risk (HR, 0.89; 95% CI, 0.66 – ...
- How to quell a cytokine storm: New ways to dampen an overactive immune systemon May 29, 2019 at 4:07 pm
BRCA DNA-repair proteins interact with a molecular complex that is also responsible for regulating the immune system. When certain players in this pathway go awry, autoimmune disorders arise. An ...
- How to quell a cytokine storm: New ways to dampen an overactive immune systemon May 29, 2019 at 10:02 am
"The important association between this complex and the immune system originally came about because my lab ... the team plans to explore designing drugs against BRISC in order to quiet overactive ...
via Bing News